Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Chemotherapy
17 evidence topics · 18 sources
NCCN placement of methotrexate-based and doxorubicin-based regimens as quoted in a payer policy
Guideline updates naming chemotherapy regimens category 2A
“Additionally, the NCCN Guidelines were updated to include methotrexate with vinorelbine; methotrexate with vinblastine, imatinib, and liposomal doxorubicin; doxorubicin with or without dacarbazine; and pazopanib as Category 2A regimens [14].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Desmoid Tumor Working Group assessment of chemotherapy
Desmoid Tumor Working Group approach to sequencing systemic therapies
Methotrexate plus vinblastine in the DESMOPAZ randomized phase 2 trial
“The proportion of patients treated with methotrexate-vinblastine who had not progressed at 6 months was 45·0% (95% CI 23·1-68·5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“in the methotrexate-vinblastine group were neutropenia (n=10, 45%) and liver transaminitis (n=4, 18%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“six patients (27%) in the methotrexate-vinblastine group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Methotrexate plus vinblastine or vinorelbine in a 25-year institutional series
“Herein, we report on our institutional experience with low-dose methotrexate (MTX) + vinca alkaloids in this disease over the last 25 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We identified 75 patients treated with MTX + vinblastine (40%), MTX + vinorelbine (57%), and vinorelbine alone (3%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eight patients interrupted chemotherapy because of toxicity. According to RECIST (Response Evaluation Criteria in Solid Tumors) complete response, partial response, stable disease, and progressive disease were observed in 1%, 47%, 51%, and 1% of patients, respectively. Symptomatic relief was obtained in 80% of symptomatic cases. The median progression-free survival (PFS) was 75 months; it was 136 months in responding patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Methotrexate plus vinorelbine in a retrospective institutional series
“Patients with biopsy‐proven DF, treated with MTX/VNL from 1997 to 2015 were reviewed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 48 patients treated for a median 19 months MTX/VNL, only nine (19%) had previous surgery.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median progression‐free survival (PFS) was 120 months, (95%CI 84‐155 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most common grade 1/2 toxicities included nausea (n = 12, 25%) and fatigue (n = 9,19%) with no grade 3/4 toxicities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Methotrexate plus vinblastine in children in a Pediatric Oncology Group phase 2 trial
“A phase II study was conducted within the Pediatric Oncology Group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were treated using Vbl (5 mg/m2/dose) and Mtx (30 mg/m2/dose), both administered by intravenous injection weekly for 26 weeks and every other week for an additional 26 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A measurable response was documented in eight patients (31%), and 10 patients had stable disease documented as the best response to treatment. Eighteen patients had disease progression at a median time of 9.1 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Neutropenia was the most common toxicity (n = 22) and the most common grade 4 toxicity (n = 5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Biweekly methotrexate plus vinblastine in a single-institution prospective cohort
“The aim of this study was to determine the clinical outcomes of a biweekly regimen in a cohort prospectively treated in our single institution.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Since 2010, we have prospectively treated refractory DF patients with biweekly MTX (30 mg/m2) + VBL (6 mg/m2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nineteen (51%) patients showed partial response (PR). Clinical benefit rate was 95%. PFS at 5 y was 80.8%. In PR cases, median time to response was 10 mo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Only 3 AEs of grade 3/4 were observed. Tumor regrowth after MTX + VBL discontinuation was observed in 5 (20%) of 25 patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Methotrexate plus vinblastine after meloxicam failure in an institutional cohort
“Since March 2003, patients pathologically diagnosed with extraperitoneal desmoid tumors have been prospectively treated with meloxicam, a COX-2 inhibitor, at our institution.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with inoperable tumors who were resistant to meloxicam treatment underwent MTX and VBL therapy every other week.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MTX + VBL therapy was administered in 15 patients. Six patients showed a partial response. Only one patient presented disease progression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of low-dose methotrexate plus vinblastine
“There were three prospective case series but no randomized controlled trials among the nine studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“According to Response Evaluation Criteria in Solid Tumors criteria, the mean response rate (complete remission or partial response) was 36% (11-57%). Including stable disease, namely, clinical benefit was consistently as high as 85% (69-100%). Mean adverse event rate of G3 or G4 according to CTCAE was 31%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, the overall evidence was weak, and this chemotherapy is not covered by insurance in Japan; we only weakly recommend low-dose chemotherapy with methotrexate and vinblastine in patients with extra-abdominal desmoid-type fibromatosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Doxorubicin-based chemotherapy in a French Sarcoma Group series
“Records of patients with DT who were treated with CT in centers from the French Sarcoma Group were reviewed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sixty-two patients entered the study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Thirteen patients (21%) received an anthracycline-containing regimen. The most frequent nonanthracycline regimen was the methotrexate-vinblastine combination (n=27).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The response rate was higher with anthracycline-containing regimens: 54% versus 12%, P=0.0011. Median progression-free survival (PFS) was 40.8 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of doxorubicin-based and liposomal doxorubicin chemotherapy
“There were no randomized controlled trials. According to response evaluation criteria in solid tumors criteria, the response rates of doxorubicin-based regimens and liposomal doxorubicin were 44% (28.6-54) and 33.3% (0-75) on average, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The rates of G3 or G4 complications according to common terminology criteria for adverse events were 28% and 13% with doxorubicin-based and liposomal doxorubicin chemotherapy, respectively, including neutropenia or cardiac dysfunction.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We weakly recommend doxorubicin-based chemotherapy for patients with extra-abdominal desmoid-type fibromatosis in cases resistant to other treatments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Anthracycline-containing regimens compared with sorafenib in a retrospective multi-institutional analysis
“The authors conducted a multi-institutional retrospective analysis of desmoid tumor patients treated with either sorafenib or an anthracycline-containing regimen over 1 year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“From 2005 to 2022, 80 patients received sorafenib and 51 received an anthracycline-containing regimen with similar baseline characteristics. The 1-year ORR was 37% for anthracycline and 13% for sorafenib (p = .016).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One-year PFS was 73% (95% CI, 60-86) for anthracycline and 59% (95% CI, 47-71) for sorafenib (p = .3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Grade 3 events were higher in the anthracycline group, 27% versus 14% (p < .05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pegylated liposomal doxorubicin in a placebo-controlled phase 3 trial
“In this investigator-initiated, double-blind, phase III trial, we randomly assigned (in a 2:1 ratio) patients with advanced or refractory DTs to receive either PLD (50 mg/m2 intravenously) or placebo every 4 weeks for six cycles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From November 2020 to March 2023, a total of 73 patients were assigned to receive PLD (49 patients) or placebo (24 patients). With a median follow-up of 16.1 months, PLD had a significantly longer PFS over placebo (not reached vs. 4.3 months), with an HR of 0.05 (95% confidence interval, 0.01–0.17; P < 0.001). The 2-year PFS rates were 90.4% with the PLD group and 19.6% with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The confirmed objective response was observed in 19 (40.4%) patients in the PLD group and in one (4.3%) in the placebo group (P = 0.002).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seven (14.9%) patients experienced grade 3 or 4 AEs in the PLD group, including neutrophil count decreased (10.6%), mucositis oral (6.4%), white cell decreased (4.3%), and palmar–plantar erythrodysesthesia syndrome (2.1%). No patients reported cardiotoxicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“First, the interpretation of our results is limited by a single-center design and relatively small sample size, which had the potential to introduce bias, although these aspects are consistent with other phase III trials in this rare disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Lastly, the current follow-up period may not be sufficient to adequately assess the cardiotoxicity associated with low cumulative doses of PLD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote